School of Radiation Medicine and Public Health, Soochow University, Suzhou, China.
BMC Cancer. 2012 Jun 13;12:239. doi: 10.1186/1471-2407-12-239.
Transforming growth factor β induced (TGFBI) product, an extracellular matrix (ECM) protein, has been implicated as a putative tumor suppressor in recent studies. Our previous findings revealed that expression of TGFBI gene is down-regulated in a variety of cancer cell lines and clinical tissue samples. In this study, ectopic expression of TGFBI was used to ascertain its role as a tumor suppressor and to determine the underlying mechanism of mesothelioma and breast cancer.
Cells were stably transfected with pRc/CMV2-TGFBI and pRc/CMV2-empty vector with Lipofectamine Plus. Ectopic expression of TGFBI was quantified by using quantitative PCR and Western-blotting. Characterization of cell viability was assessed using growth curve, clonogenic survival and soft agar growth. The potential of tumor formation was evaluated by an in vivo mouse model. Cell cycle was analyzed via flow cytometry. Expressions of p21, p53, p16 and p14 were examined using Western-blotting. Senescent cells were sorted by using a Senescence β-Galactosidase Staining Kit. Telomerase activity was measured using quantitative telomerase detection kit.
In this study, an ectopic expression of TGFBI in two types of cancer cell lines, a mesothelioma cell line NCI-H28 and a breast cancer cell line MDA-MB-231 was found to have reduced the cellular growth, plating efficiency, and anchorage-independent growth. The tumorigenicity of these cancer cell lines as determined by subcutaneous inoculation in nude mice was similarly suppressed by TGFBI expression. Likewise, TGFBI expression reduced the proportion of S-phase while increased the proportion of G1 phase in these cells. The redistribution of cell cycle phase after re-expression of TGFBI was correspondent with transiently elevated expression of p21 and p53. The activities of senescence-associated β-galactosidase and telomerase were enhanced in TGFBI-transfected cells.
Collectively, these results imply that TGFBI plays a suppressive role in the development of mesothelioma and breast cancer cells, possibly through inhibitions of cell proliferation, delaying of G1-S phase transition, and induction of senescence.
转化生长因子 β 诱导(TGFBI)产物是细胞外基质(ECM)蛋白,最近的研究表明其作为一种潜在的肿瘤抑制因子。我们之前的研究结果表明,TGFBI 基因在多种癌细胞系和临床组织样本中表达下调。在这项研究中,我们通过脂质体转染法将 TGFBI 过表达质粒转染入细胞,以确定其作为肿瘤抑制因子的作用,并确定间皮瘤和乳腺癌的潜在机制。
细胞用 Lipofectamine Plus 稳定转染 pRc/CMV2-TGFBI 和 pRc/CMV2-empty 载体。通过定量 PCR 和 Western-blotting 检测 TGFBI 的过表达情况。通过生长曲线、集落形成实验和软琼脂生长实验评估细胞活力的变化。通过体内小鼠模型评估肿瘤形成的潜力。通过流式细胞术分析细胞周期。通过 Western-blotting 检测 p21、p53、p16 和 p14 的表达。通过 Senescence β-Galactosidase Staining Kit 分选衰老细胞。通过定量端粒酶检测试剂盒测量端粒酶活性。
在这项研究中,我们发现两种类型的癌细胞系,间皮瘤细胞系 NCI-H28 和乳腺癌细胞系 MDA-MB-231 中 TGFBI 的过表达可降低细胞生长、铺板效率和锚定非依赖性生长。TGFBI 表达同样抑制这些癌细胞系在裸鼠皮下接种的致瘤性。同样,TGFBI 表达降低了这些细胞中 S 期的比例,同时增加了 G1 期的比例。TGFBI 重新表达后细胞周期的重新分布与 p21 和 p53 的短暂上调相对应。衰老相关β-半乳糖苷酶和端粒酶的活性在 TGFBI 转染的细胞中增强。
综上所述,这些结果表明 TGFBI 在间皮瘤和乳腺癌细胞的发生发展中发挥抑制作用,可能通过抑制细胞增殖、延缓 G1-S 期转化和诱导衰老来实现。